Eli Lilly has exercised its option to include amylin receptor agonists in its collaboration with Camurus, extending its exclusive global rights to Camurus' FluidCrystal technology. This expands Lilly's development and commercialization efforts to cover up to four drug compounds across three classes, including dual and triple receptor agonists. Camurus will receive an initial $5 million payment and is eligible for up to $870 million in milestone payments plus royalties. This move validates Camurus' technology and strengthens the partnership, potentially advancing new long-acting cardiometabolic therapies.
Major investors are increasingly focusing on AI-driven biology and longevity, with startups like NewLimit tripling in value. While many of these startups remain private, NVIDIA and Eli Lilly stand out as the main public companies involved, partnering...
Eli Lilly reported a 55.5% revenue increase in Q1, driven by strong sales of Mounjaro and Zepbound totaling $12.8 billion. Despite this growth, shares have only risen slightly due to pricing pressures and charges from acquisitions and litigation. The...
Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, ...
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
Eli Lilly announced positive Phase 3 BRUIN CLL-322 study results showing that adding pirtobrutinib to venetoclax and rituximab significantly improves progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
